Several neurological problems can arise in cancer (Table 1) . This article will focus on the most challenging presentations. Treatment related complications will not be discussed.
Metastasis

Brain metastases
Brain metastases are common (10-30% of cancer patients). The prevalence is rising as survival improves, the population ages and clinically silent lesions are detected with magnetic resonance imaging (MRI). The most common primaries in adults are lung (50%), breast (15-20%) and melanoma (10%). Lung and melanoma tend to produce multiple metastases, limiting treatment options. 1, 2 The distribution of brain metastases occurs in proportion to blood flow (80% cerebral hemispheres, 15% cerebellum, 5% brainstem). Patients present with headaches, seizures and cognitive dysfunction or progressive focal neurological deficits such as hemiparesis, aphasia or visual field defect. Up to a third of metastases escape detection during life. 3 Brain metastases are associated with a poor prognosis. Depending on age, functional status, extent of systemic disease and number of metastases, median survival is 2.3-13.5 months. 4 Contrast enhanced MRI is the most sensitive test; if a single metastasis is seen on computed tomography (CT), MRI is required to exclude multiple metastases before planning radical treatment. Initial medical management consists of steroids for oedema and anticonvulsants where appropriate. Further treatment may consist of surgical excision or radiosurgery for a solitary metastasis or whole brain radiotherapy. 5, 6 Spinal cord compression Approximately 5% of cancer patients develop spinal cord compression, in twothirds of cases in the narrower thoracic canal. Bony spinal metastases arise from any primary malignancy, the most common being prostate, breast and lung. 5 Spinal pain is common; it presents on average 7-15 weeks before neurological signs develop, most commonly as bilateral pyramidal leg weakness. The site of pain or sensory level does not correlate well with the level of cord compression. A high level of suspicion is required and a spine MRI is the investigation of choice. Treatment is with steroids, usually followed by either surgery or radiotherapy. 5 
Neoplastic meningitis
Neoplastic meningitis (NM), resulting from direct invasion of leptomeninges and/or cerebrospinal fluid (CSF) by cancer cells, occurs in 3-8% of cancer patients, with a higher incidence at postmortem. The incidence is increasing because of more accurate MRI imaging and improved prognosis with more effective systemic disease treatments. Interestingly, the incidence is higher for breast cancer (12-34%) than for lung cancer (10-26%), the inverse of brain metastases. 7, 8 Other common solid tumour primaries for NM include melanoma and gastrointestinal tumours. NM occurs in 7-15% of non-Hodgkin's lymphoma and 5-15% of leukaemias (mainly acute non-lymphocytic). It is also found in primary brain tumours, particularly ependymoma and medulloblastoma. NM arises via haematogenous spread, direct invasion from metastases, perineural space spread and seeding during surgical resection.
Clinical findings and imaging
Symptoms and signs vary according to the part of the neuroaxis affected ( Table 2 ). The possibility of NM must always be considered in established cancer cases. There should be high clinical suspicion of NM in multifocal neuroaxis disease with 'lymphocytic meningitis' in patients not known to have cancer.
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Clinical Medicine Contrast-enhanced MRI is more sensitive than CT (71% v 29%) 8 and both linear and nodular enhancement can be found (Fig 1(a) to 1(d)). There can be a lack of correlation between imaging findings and symptoms and signs. An MRI of the brain and spine is required for proper assessment of the full extent of NM.
Cerebrospinal fluid analysis
CSF analysis is the most useful test for diagnosing NM and monitoring treatment. The CSF shows abnormalities in nearly all patients (Table 3) . 8, 9 Malignant cells may be found at different neuroaxis levels. Lumbar CSF is more sensitive, than CSF from other neurological levels, while positive lumbar cytology correlates better with imaging. There is frequently dissociation (<30%) between CSF white cell count and cytology. 7 The volume of CSF is critical (10 ml is ideal). Initial lumbar CSF is positive in 55% of NM; a second CSF increases this to 80%. Returns diminish with repeated testing, and some cases remain cytology negative. 8 
Diagnosis, prognosis and treatment
A pathological definition of NM is positive CSF cytology, irrespective of neuroimaging. NM is clinically defined when CSF cytology is negative but there is pathologically proven cancer and a clinical syndrome consistent with NM. 7 It is important to exclude mimicking conditions such as infections. 9 Clinical condition is important in determining prognosis, encephalopathy being a poor prognostic sign. 10 Most NM patients present with advanced disease and are best offered supportive palliative care which might include radiotherapy for focal disease and anticonvulsants. Overall survival is short (2-6 months). The mainstays of aggressive therapy, where indicated, are intrathecal and systemic chemotherapy (Table 4) ; the former may require surgery to implant an Ommaya reservoir. 8 
Paraneoplastic neurological disorders
Paraneoplastic neurological disorders (PND) represent less than 1% of neurological cancer complications but are important as they usually occur before a cancer diagnosis. 11, 12 The underlying cancer is almost always localised, therefore the chances of cure are highest. PND can affect any part of the nervous system (Table 5) , causing significant morbidity and mortality. In some PNDs associated with certain cancers antibodies are found in serum and CSF ( the most common PND, occurring in 2-3% of small cell lung cancer (SCLC) cases. PND rarely occurs in young people, 13 although this depends on the peak incidence for the associated cancer.
The most common cancers associated with PND are SCLC, breast, gynaecological and lymphoma. In up to 20% of PND no cancer is found at post-mortem, the hypothesis being that host immunity has fully controlled the tumour.
PND can affect a single neural component or several simultaneously. In the relatively common encephalomyelitis the areas most frequently involved are the hippocampus, brainstem, spinal cord and dorsal root ganglia. There is an underlying SCLC in more than 85% of cases. The differential of PND may include granulomatous, vasculitic, inflammatory and infective conditions. PND more commonly affects the peripheral nervous system, where it tends to be of gradual onset, than the central nervous system (CNS) where onset can be rapid usually over weeks to months.
Central nervous system
Limbic encephalitis presents with recent memory loss and altered mental state, which can progress to agitation, dementia and seizures. An important differential is herpes simplex encephalitis. MRI can be normal or show medial temporal lobe signal changes (Fig 2(a) and 2(b) ) and the CSF may show elevated protein and lymphocytosis. The most common association is with SCLC and anti-Hu antibodies or sometimes anti-Ma1 or ANNA-3. Other antibody associations are anti-Ma2 or anti-CV2 antibodies (Table 6 ). MRI can be normal but later shows cerebellar atrophy. Common antibody associations are anti-Yo and anti-Hu, less well characterised antibodies associated with Hodgkin's disease are anti-Tr and anti-mGluR1.
Brainstem encephalitis
Stiff-person syndrome. This syndrome is characterised by axial muscle stiffness, superimposed painful muscle spasms and continuous muscle activity on electromyography. Rare cases are paraneoplastic. Anti-amphiphysin antibodies can be found.
Retinal degeneration causes bilateral, painless visual failure and is associated with antirecoverin antibodies, SCLC and gynaecological cancers.
Motor neurone diseases. The concept of these disorders as a PND is unresolved. 12 
Peripheral nervous system
Neuromuscular junction and muscle
Lambert-Eaton myasthenic syndrome.
There is fatiguable muscle weakness, usually primarily of proximal lower limbs, with autonomic features (dry mouth, impotence and constipation), reflexes are reduced/absent and potentiated after brief muscle contraction. 
Clinical Medicine
Diagnostic tests
Standard blood tests, MRI scans, CSF analysis and clinical neurophysiology are used primarily to exclude other diagnoses. PND is confirmed by the presence of known paraneoplastic antibodies and/or an underlying cancer. 14 Screening for an underlying cancer may need to continue for three years when initially negative. Paraneoplastic antibodies (Table 6 ) are produced by an autoimmune response against common antigens to cancer and neuronal cells. Direct evidence that these antibodies are pathogenic is lacking except in Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis.
Underlying cancer may be smaller than CT resolution limits, but 18F-fluoro-2-deoxyglucose-positron emission tomography can identify small lesions and guide further investigation. 15 
Treatment and prognosis
Treatment is primarily targeted at the underlying tumour which may also reduce the risk of spread. Generally CNS PNDs respond less well than other PNDs, such as LEMS, to immunomodulatory treatments (steroids, azathioprine and intravenous immunoglobulin). 11, 12 Patients with a CNS PND can be stablised but may remain disabled, probably due to irreversible neuronal cell death.
